Short answer
Suboxone can block or strongly blunt the opioid-like effects of kratom. It does not block every kratom effect.
Kratom is biphasic. At lower doses, many users describe stimulant-like effects: alertness, energy, focus, and mild mood lift. At higher doses, kratom tends to feel more opioid-like: sedation, pain relief, warmth, euphoria, and withdrawal relief. Those higher-dose opioid-like effects are mainly related to activity at the mu-opioid receptor.
Buprenorphine, the active opioid medication in Suboxone, binds tightly to that same receptor. When buprenorphine is occupying the receptor, kratom alkaloids have a harder time activating it. That is why patients on therapeutic-dose buprenorphine often report that high-dose kratom, kratom extracts, or 7-OH products feel weaker or do very little.
The important limits:
- Suboxone should not be described as blocking all kratom effects.
- Controlled clinical trials have not specifically tested buprenorphine as a kratom-blocking medication.
- The bigger safety issue is often the reverse: starting Suboxone too soon after kratom or 7-OH can trigger precipitated withdrawal.
The mechanism
How buprenorphine interacts with kratom — and the limits.
Kratom contains many alkaloids. The two most important for this discussion are:
Mitragynine: The most abundant kratom alkaloid by mass. It has partial mu-opioid activity and also appears to act through non-opioid systems, including adrenergic and serotonergic pathways. This is one reason kratom does not behave like a clean, classical opioid.
7-hydroxymitragynine, often called 7-OH: Usually present only in trace amounts in natural kratom leaf, but it can also be formed when the liver metabolizes mitragynine. Concentrated 7-OH products are a separate and higher-risk category. These products may be sold as tablets, drinks, shots, gummies, or high-potency extracts.
Buprenorphine binds tightly to the mu-opioid receptor and tends to stay there. While buprenorphine is occupying that receptor, mitragynine and 7-OH have less opportunity to produce opioid-like effects at that site.
What buprenorphine does not do: it does not block kratom’s adrenergic activity, serotonergic activity, or every non-opioid alkaloid effect. That matters clinically because some people who continue using kratom despite starting Suboxone may still notice energy, focus, stimulation, or ritual reinforcement from lower-dose kratom use. This is a reason the habit can persist; it is not a reason to intentionally combine the two.
What the evidence supports
The science is supportive but not conclusive.
PET imaging studies show that therapeutic buprenorphine doses can occupy a high percentage of mu-opioid receptors. That supports the mechanism for opioid blockade. But those studies were not kratom studies. They were conducted in opioid-dependent volunteers and measured mu-opioid receptor availability and response to opioid challenge, not kratom response.
For kratom withdrawal or kratom use disorder, the published evidence for buprenorphine is mostly case reports and expert clinical experience. The University of Illinois Chicago Drug Information Group specifically notes that there are no clinical trials and no published guidelines that establish buprenorphine or buprenorphine-naloxone as a standard treatment for kratom withdrawal.
That does not mean buprenorphine is inappropriate. It means the right wording is: buprenorphine may be appropriate case by case, especially for high-dose kratom use, concentrated 7-OH use, prior opioid use disorder, severe withdrawal, or repeated failed quit attempts.
What patients may notice
If kratom use continues despite Suboxone treatment.
Suboxone treatment is generally meant to treat kratom or 7-OH use, not to be taken alongside it. The points below are harm-reduction observations for patients who have already used both, had a return to use, or are still struggling to stop kratom after starting treatment. They are not instructions to combine kratom with Suboxone.
If a person uses higher-dose kratom, extracts, or 7-OH products after reaching a therapeutic Suboxone dose, many patients report:
- Less euphoria or no euphoria.
- Less withdrawal relief from kratom.
- Less sedation or opioid-like effect.
- A sense that kratom is no longer doing what it used to do.
If a person uses lower-dose kratom despite being on Suboxone, some patients still report:
- Energy.
- Focus.
- Mild stimulation.
- A behavioral pull to keep dosing, even without much opioid-like effect.
This is not necessarily Suboxone failing. It reflects kratom’s mixed pharmacology. Clinically, the goal is usually to stop kratom or 7-OH and stabilize on the treatment plan, not to use both ongoing.
The reverse risk
Starting Suboxone too soon is the more important risk.
The more clinically important risk often goes the other direction.
If kratom or 7-OH is still active at the mu-opioid receptor when buprenorphine arrives, buprenorphine can displace it and produce a lower net opioid effect. That can cause sudden worsening of withdrawal. This is called precipitated withdrawal.
Symptoms may include sweating, anxiety or panic, nausea or vomiting, diarrhea, cramps, restlessness, muscle aches, and intense cravings.
The Suboxone prescribing information warns that buprenorphine can precipitate opioid withdrawal if it is started before the effects of a full opioid agonist have subsided. Kratom is not a classical opioid, and there is no universally established wait time for kratom or 7-OH. Time since last use helps, but it should not be the only factor. Clinicians usually look for objective withdrawal and may use tools such as COWS or SOWS, while recognizing that those tools were not designed specifically for kratom.
For higher-dose kratom users, concentrated 7-OH users, or patients who cannot tolerate a full washout, microinduction may be considered by an experienced clinician.
Combined use
Can you take kratom while on Suboxone?
In general, patients should not plan to take kratom or 7-OH at the same time as Suboxone unless a clinician is directly supervising a specific transition plan. Suboxone treatment is usually used to help stop kratom or 7-OH use, reduce withdrawal, and stabilize cravings, not to make ongoing kratom use safer.
If kratom use continues, or if a return to use happens after starting Suboxone, it is medically important to tell your MyStreetHealth prescriber. Disclosure is not about punishment; it helps the clinician adjust the plan safely.
Three practical issues matter:
- The behavior pattern may stay active. Even if buprenorphine blocks much of the opioid-like effect, the cycle of buying, dosing, expecting relief, and checking how you feel can continue.
- The lower-dose stimulant effect may not be blocked. That can keep the habit alive even after the opioid-like effect is reduced.
- Combination risk can increase sedation. Kratom at higher doses, 7-OH products, Suboxone, alcohol, benzodiazepines, gabapentin, pregabalin, muscle relaxers, sleep medications, and other sedatives can combine in unsafe ways.
Honest disclosure usually leads to better care. It is more useful than waiting to see whether a urine test detects kratom.
Treatment
Treatment for kratom and 7-OH dependence is available online.
MyStreetHealth treats kratom and 7-OH dependence through secure telehealth visits in Virginia, West Virginia, Maryland, Washington DC, and Ohio. Same-day visits are often available. No insurance is required.
Buprenorphine is one option, not the only option. It is not automatically the right answer for every kratom patient. Some patients do better with tapering, supportive treatment, or a structured plan without buprenorphine. Others, especially high-dose kratom or 7-OH users, may benefit from medication treatment.
Medical note
Kratom and 7-OH products vary widely in strength, purity, labeling accuracy, and legal status. This page is educational and does not replace medical care. Seek urgent medical advice for jaundice, severe vomiting or dehydration, chest pain, confusion, fainting, seizure, severe sedation, slowed breathing, pregnancy, or use with alcohol, benzodiazepines, opioids, gabapentin, pregabalin, or other sedatives.